生长抑素类似物在肢端肥大症治疗中的意义
Implications of Somatostatin Analogues in the Treatment of Acromegaly.
作者信息
Gariani Karim, Meyer Patrick, Philippe Jacques
机构信息
Chief Resident, Internal Medicine Service.
Associate Clinician.
出版信息
Eur Endocrinol. 2013 Aug;9(2):132-135. doi: 10.17925/EE.2013.09.02.132. Epub 2013 Aug 23.
Abstract
Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects of octreotide treatment.
摘要
奥曲肽在肢端肥大症的医学管理中具有重要作用。其作为神经外科手术后辅助治疗在肢端肥大症管理中的地位已得到充分确立，疗效也得到了充分证明。它还可在某些临床情况下用作新辅助治疗。临床医生和患者应了解奥曲肽治疗可能产生的副作用。
相似文献
1
Implications of Somatostatin Analogues in the Treatment of Acromegaly.生长抑素类似物在肢端肥大症治疗中的意义
Eur Endocrinol. 2013 Aug;9(2):132-135. doi: 10.17925/EE.2013.09.02.132. Epub 2013 Aug 23.
2
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.生长抑素类似物在肢端肥大症和胃肠胰神经内分泌肿瘤中的应用：过去、现在与未来
Endocr Relat Cancer. 2016 Dec;23(12):R551-R566. doi: 10.1530/ERC-16-0151. Epub 2016 Oct 3.
3
Medical therapy for acromegaly.肢端肥大症的医学治疗
Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90. doi: 10.1016/s0889-8529(05)70062-1.
4
Pegvisomant Treatment in Acromegaly.培维索孟治疗肢端肥大症
Neuroendocrinology. 2016;103(1):59-65. doi: 10.1159/000381644. Epub 2015 Mar 19.
5
Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.肢端肥大症的药物治疗：生长抑素类似物的疗效与安全性
Drugs. 2009 Nov 12;69(16):2207-26. doi: 10.2165/11318510-000000000-00000.
6
Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues.肢端肥大症患者对生长抑素（SST）类似物出现部分快速减敏反应：SST受体脱敏及循环中抗SST类似物抗体的作用
Eur J Endocrinol. 2002 Mar;146(3):295-302. doi: 10.1530/eje.0.1460295.
7
The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.急性奥曲肽抑制试验在预测活动性肢端肥大症患者对长效生长抑素类似物长期反应中的价值。
Clin Endocrinol (Oxf). 2005 Mar;62(3):282-8. doi: 10.1111/j.1365-2265.2004.02191.x.
8
The role of somatostatin receptors in the medical treatment of acromegaly.生长抑素受体在肢端肥大症医学治疗中的作用。
Dig Liver Dis. 2004 Feb;36 Suppl 1:S55-9. doi: 10.1016/j.dld.2003.11.022.
9
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.生长抑素类似物疗法对肢端肥大症患者垂体瘤体积的影响。
Pituitary. 2016 Apr;19(2):210-21. doi: 10.1007/s11102-015-0677-y.
10
From somatostatin to octreotide LAR: evolution of a somatostatin analogue.从生长抑素到奥曲肽 LAR：生长抑素类似物的演变。
Curr Med Res Opin. 2009 Dec;25(12):2989-99. doi: 10.1185/03007990903328959.
引用本文的文献
1
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.奥曲肽长效注射剂（CAM2029）治疗肢端肥大症的群体药代动力学分析
Clin Pharmacokinet. 2025 May 26. doi: 10.1007/s40262-025-01522-3.
2
Risk of intracranial meningioma in patients with acromegaly: a systematic review.肢端肥大症患者颅内脑膜瘤的风险：系统评价。
Front Endocrinol (Lausanne). 2024 Jun 11;15:1407615. doi: 10.3389/fendo.2024.1407615. eCollection 2024.
3
The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.受体-配体相互作用在生长抑素信号通路中的作用：对神经内分泌肿瘤的影响
Cancers (Basel). 2023 Dec 25;16(1):116. doi: 10.3390/cancers16010116.
4
Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis.肢端肥大症的治疗模式、依从性、持续性及医疗资源利用：一项真实世界分析
J Endocr Soc. 2023 Aug 23;7(10):bvad104. doi: 10.1210/jendso/bvad104. eCollection 2023 Aug 28.
5
Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines.阑尾神经内分泌肿瘤的管理：当前指南见解
Cancers (Basel). 2022 Dec 31;15(1):295. doi: 10.3390/cancers15010295.
6
Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.垂体神经内分泌肿瘤中组学生物标志物概述，以设计未来的诊断和治疗策略。
EPMA J. 2021 Jun 26;12(3):383-401. doi: 10.1007/s13167-021-00246-1. eCollection 2021 Sep.
本文引用的文献
1
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.肢端肥大症患者皮下注射培高利特的长期疗效和安全性：一项开放性、多中心、II 期扩展研究的结果。
Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0.
2
Oxalate nephropathy induced by octreotide treatment for acromegaly: a case report.奥曲肽治疗肢端肥大症所致草酸钙肾病：一例报告
J Med Case Rep. 2012 Jul 23;6:215. doi: 10.1186/1752-1947-6-215.
3
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.肢端肥大症患者使用培维索孟的长期安全性：ACROSTUDY 中 1288 例患者的综合评估。
J Clin Endocrinol Metab. 2012 May;97(5):1589-97. doi: 10.1210/jc.2011-2508. Epub 2012 Feb 22.
4
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.奥曲肽 LAR 和兰瑞肽长效微球作为肢端肥大症术后治疗的比较。
Pituitary. 2012 Sep;15(3):398-404. doi: 10.1007/s11102-011-0335-y.
5
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.美国临床内分泌医师协会肢端肥大症诊断与治疗临床实践医学指南——2011年更新版
Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44. doi: 10.4158/ep.17.s4.1.
6
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature.肢端肥大症患者的妊娠：来自两个转诊中心的经验和文献系统综述。
Clin Endocrinol (Oxf). 2012 Feb;76(2):264-71. doi: 10.1111/j.1365-2265.2011.04180.x.
7
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.未选择的初发肢端肥大症患者术前奥曲肽治疗 6 个月：对生化指标、肿瘤体积和术后治愈的影响。
Clin Endocrinol (Oxf). 2011 Jun;74(6):736-43. doi: 10.1111/j.1365-2265.2011.03982.x.
8
Place of cabergoline in acromegaly: a meta-analysis.卡麦角林治疗肢端肥大症的疗效评价：一项荟萃分析。
J Clin Endocrinol Metab. 2011 May;96(5):1327-35. doi: 10.1210/jc.2010-2443. Epub 2011 Feb 16.
9
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.肢端肥大症患者生长抑素受体配体剂量递增的临床疗效和安全性结果：文献综述。
Pituitary. 2011 Jun;14(2):184-93. doi: 10.1007/s11102-010-0282-z.
10
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study.术前长效奥曲肽治疗侵袭性垂体大腺瘤伴肢端肥大症患者的效果：一项前瞻性随机研究。
Endocr J. 2010;57(12):1035-44. doi: 10.1507/endocrj.k10e-203. Epub 2010 Nov 16.
Zotero 插件